<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001619</url>
  </required_header>
  <id_info>
    <org_study_id>970026</org_study_id>
    <secondary_id>97-H-0026</secondary_id>
    <nct_id>NCT00001619</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging at Different Levels of Magnetic Intensity</brief_title>
  <official_title>Magnetic Resonance at 1.5 and 3 Tesla</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Magnetic resonance imaging (MRI) is a diagnostic tool that creates high quality images of the
      human body without the use of X-ray (radiation). MRI uses different levels of magnetic fields
      to create images of the body and organs. Occasionally, researchers will give patients
      undergoing a MRI an injection of a substance called gadolinium. Gadolinium works by
      brightening areas of the magnetic resonance image, thereby improving the contrast.

      In this study researchers will use magnetic resonance imaging and contrast substances, like
      gadolinium, on normal volunteers in order to evaluate different aspects of its performance.
      Information gathered from this study may be used to develop more specific research studies
      involving MRI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Technical evaluation of magnetic resonance imaging and spectroscopy will be performed on
      normal volunteers. These studies will be conducted in the MRI systems located at the NIH.
      These studies may involve the intravenous administration of commercially available MR
      contrast media and exercise. The results will be used to evaluate the performance of various
      pulse sequences, gradient coils, and RF coils on human subjects and will provide essential
      ground work for specific patient protocols.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 5, 1996</start_date>
  <completion_date>July 20, 2011</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment type="Actual">497</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Healthy</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Any normal volunteer greater than or equal to 18 who is capable of giving informed consent.

        EXCLUSION CRITERIA:

        A subject will be excluded if he/she has a contraindication to MR scanning such as:

          1. Brain aneurysm clip

          2. Implanted neural stimulator

          3. Implanted cardiac pacemaker or defibrillator

          4. Cochlear or ear implant

          5. Ocular foreign body (e.g. metal shavings)

          6. Insulin pump

          7. Pregnant women (when uncertain, subject will undergo urine or blood testing).

          8. Claustrophobia

          9. Any condition in the Principal Investigator's judgement which present unnecessary risk

        EXCLUSION CRITERIA FOR GADOLINIUM ENHANCED STUDIES:

          1. Lactating Women

          2. Renal or hepatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mattay VS, Weinberger DR, Barrios FA, Sobering GS, Kotrla KJ, van Gelderen P, Duyn JH, Sexton RH, Moonen CT, Frank JA. Brain mapping with functional MR imaging: comparison of gradient-echo--based exogenous and endogenous contrast techniques. Radiology. 1995 Mar;194(3):687-91.</citation>
    <PMID>7862963</PMID>
  </reference>
  <reference>
    <citation>Niendorf HP, Dinger JC, Haustein J, Cornelius I, Alhassan A, Clauss W. Tolerance data of Gd-DTPA: a review. Eur J Radiol. 1991 Jul-Aug;13(1):15-20. Review.</citation>
    <PMID>1889423</PMID>
  </reference>
  <reference>
    <citation>Frank JA, Mattay VS, Duyn J, Sobering G, Barrios FA, Zigun J, Sexton R, Kwok P, Woo J, Moonen C, et al. Measurement of relative cerebral blood volume changes with visual stimulation by 'double-dose' gadopentetate-dimeglumine-enhanced dynamic magnetic resonance imaging. Invest Radiol. 1994 Jun;29 Suppl 2:S157-60.</citation>
    <PMID>7928216</PMID>
  </reference>
  <verification_date>July 20, 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <keyword>Imaging</keyword>
  <keyword>Spectroscopy</keyword>
  <keyword>MRI</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>Technical Development</keyword>
  <keyword>Heart</keyword>
  <keyword>Safety</keyword>
  <keyword>Toxicity</keyword>
  <keyword>Gadolinium</keyword>
  <keyword>Adverse Events</keyword>
  <keyword>Normal Volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

